Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
United Acquisition Q2 net income rises to $691,371

United Acquisition Q2 net income rises to $691,371

ReutersReuters2026/08/12 20:28
  • United Acquisition posted net income of USD 691,371 for the three months ended June 30, 2026.
  • Interest earned on marketable securities in the Trust Account totaled USD 905,837, offset by general and administrative expenses of USD 214,466.
  • For the six months ended June 30, 2026, net income was USD 1.05 million on Trust Account interest of USD 1.48 million.
  • General and administrative expenses were USD 511,978; results also included a USD 82,463 change in the over-allotment liability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Acquisition Corp. I published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037369), on August 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well